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Background: Silver nanoparticles (AgNPs), owing to their effective antimicrobial properties, are being widely used in a
broad range of applications. These include, but are not limited to, antibacterial materials, the textile industry, cosmetics,
coatings of various household appliances and medical devices. Despite their extensive use, little is known about AgNP
safety and toxicity vis-à-vis human and animal health. Recent studies have drawn attention towards potential neurotoxic
effects of AgNPs, however, the primary cellular and molecular targets of AgNP action/s remain to be defined.
Results: Here we examine the effects of ultra fine scales (20 nm) of AgNPs at various concentrations (1, 5, 10 and
50 μg/ml) on primary rat cortical cell cultures. We found that AgNPs (at 1-50 μg/ml) not only inhibited neurite
outgrowth and reduced cell viability of premature neurons and glial cells, but also induced degeneration of neuronal
processes of mature neurons. Our immunocytochemistry and confocal microscopy studies further demonstrated that
AgNPs induced the loss of cytoskeleton components such as the β-tubulin and filamentous actin (F-actin). AgNPs also
dramatically reduced the number of synaptic clusters of the presynaptic vesicle protein synaptophysin, and the
postsynaptic receptor density protein PSD-95. Finally, AgNP exposure also resulted in mitochondria dysfunction in rat
cortical cells.
Conclusions: Taken together, our data show that AgNPs induce toxicity in neurons, which involves degradation of
cytoskeleton components, perturbations of pre- and postsynaptic proteins, and mitochondrial dysfunction leading to
cell death. Our study clearly demonstrates the potential detrimental effects of AgNPs on neuronal development and
physiological functions and warns against its prolific usage.
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Nanoparticles are ultra-fine materials (range of 1-100
nm in length or diameter) that have gained enormous
popularity in modern technology, medical health care,
and commercial products [1-3]. Silver nanoparticles
(AgNPs) are one of the most commonly used metal-
nanoparticles, which possess potent antibacterial and
antifungal characteristics. AgNPs have been used exten-
sively as an antimicrobial agent in cosmetics, textiles
and the food industry, as well as a disinfectant for* Correspondence: fxu@ucalgary.ca; nisyed@ucalgary.ca
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reproduction in any medium, provided the ormedical devices and for coating home applicance [4].
AgNPs upon entering the human body can be systemic-
ally distributed throughout, and may affect organs like
the lung, liver, spleen, kidney and the central nervous
system (CNS) [5-7]. Although various organs can rid
themselves of AgNPs, these particles tend to reside for a
considerable time, and exhibit a longer half-life within
the brain than in other organs [8]. AgNPs could gain ac-
cess to the CNS through the upper respiratory tract via
the olfactory bulb [9] or through the blood–brain barrier
(BBB) [5,8,10] and accumulate in various brain regions
[4,11]. AgNPs are also known to cause inflammation and
disruption of the BBB [12]. Although the translocation
of AgNPs into the brain through the BBB is fairly low
under normal condition, its accumulation is augmented
under pathological conditions such as meningitis, stroke,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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potential health risks within the brain when exposed to,
or upon consumption of AgNP-containing substances.
In the past several years, researchers have begun to ex-
plore the potential neurotoxicity of AgNPs using animal
models and primary neuronal cell cultures. For instance,
studies have reported that animals treated with AgNPs
exhibited cognitive impairment, motor deficits and cellu-
lar alterations in the brain [8]. In AgNP-treated zebrafish
embryos, AgNPs have been found to mainly distribute in
the brain, heart, and the blood. Accordingly, AgNPs
resulted in cardiorespiratory arrhythmicity, slow blood
flow, and impaired body movement and development
[14,15]. In mixed primary neuronal cell cultures of
mouse frontal cortex, AgNPs have been found to induce
acute intracellular calcium rise followed by a strongFigure 1 Exposure to AgNPs compromises neuronal viability and per
neurons cultured either in the absence (A, control) or presence of various c
Shows the control group grown in the absence of AgNPs is characterized
(indicated by an arrow, also see insert). (B) Shows that AgNPs at the conce
triggered fragmentation of developing neuronal networks (indicated by an
5 μg/mL have an increased number of deteriorating cells (indicated by an
(indicated by an arrow). (D) In the presence of AgNPs at 10 μg/mL, the ma
sprouting and outgrowth. Arrows indicate neuronal processes and asterisksoxidative stress response and cytotoxicity in both neu-
rons and glial cells [16]. Glial cells were found in this
study to be more vulnerable to AgNP toxicity than neu-
rons. Other studies have revealed that AgNPs could alter
excitatory glutamatergic synaptic transmission and re-
ceptor functions [16]. It could also change cellular
excitability by affecting voltage-gated sodium [17] and
potassium channels [18] in primary CA1 neurons from
mice.
Despite the potential effects of AgNP neurotoxicity
cited above, it is still not known whether these
nanoparticles could differentially affect brain tissues in
the early developmental stage versus later growth
phases. It is also unclear whether AgNPs affect funda-
mental structural and functional components such as
the cytoskeleton, mitochondria and synaptic machinery.turbs neurite outgrowth. Phase contrast images of rat cortical
oncentrations of AgNPs at 1 (B), 5 (C), and 10 (D) μg/ml for 3 days. (A)
by healthy cell bodies and well-established neuronal processes
ntration of 1 μg/mL caused cell damage (indicated by an asterisk) and
arrow) (also see insert). (C) Indicates that cells cultured in AgNPs at
asterisk) and a markedly reduced degree of neurite outgrowth
jority of cells underwent cell death and abnormal/limited neuronal
indicate neuronal cell bodies. Scale bar, 25 μm.
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AgNPs on neurite outgrowth and cell viability during
both early (< 6 days in culture) and more mature
(> 10 days) developing stages. We found that AgNPs
(20 nm) reduced cell viability in both the early and later
stage of cultures in a concentration-dependent manner.
Specifically, AgNPs not only inhibited the sprouting of
neuronal branches and elongation of neurites, but also
caused fragmentation and degeneration of mature neu-
rons. Our data further demonstrated that AgNP neuro-
toxicity involves the perturbation of structural and/or
functional integrity of cytoskeletal components, mito-
chondria and synaptic proteins.
Results
AgNPs inhibit neuronal extension, neuritic overlap, and
compromise cell viability of cultured rat cortical cells
To examine the effect of AgNPs on brain cell develop-
ment, we first investigated whether AgNPs affect neurite
initiation, extension and neuritic overlap. To this end,
cells were cultured either in the absence or presence of
AgNPs at concentrations of 1, 5, 10, and 50 μg/ml
for 3 days. Representative phase contrast images
(Figure 1A-1D) were taken on day 3 to evaluate the ef-
fect of AgNPs on the development of neurite processes,
branches, and overlaps. A Live/Dead cell assay (see
Methods) was subsequently performed the same day to
evaluate the effect of AgNPs on cell survival. Figure 1A
shows that in the absence of AgNPs (as control), cells
exhibit healthy cell bodies, extensive branches and over-
lap (indicated by arrows, also see insert). Despite the fact
that cells cultured in the presence of AgNPs at a concen-
tration of 1 μg/ml still form overlaps, the number and
degree of cell overlaps were apparently not as extensive
when compared to control (Figure 1B). Note that a sub-
population of cell bodies underwent cell death (indicated
by asterisks) and some of the neuronal processes
appeared fragmented (indicated by an arrow) (Figure 1B,
also see insert). Increasing concentrations of AgNPs to 5
and 10 μg/ml augmented the detrimental effect of
AgNPs on cell death (indicated by asterisks) and severely
diminished the extension of neurites and the degree of
neuritic overlaps (indicated by arrows) (Figure 1C and
1D). To further quantify the effect of AgNPs on cell via-
bility, we subsequently performed a Live/Dead cell assay
on cells cultured either in the absence or presence of
AgNPs for 3 days. To do this, cells were incubated using
the Viability ⁄ Cytotoxicity Kit (Invitrogen) for 15 mins at
room temperature. Fluorescent images of live and dead
cells were taken using a confocal microscope (LSM-510)
and images were acquired through a 20× objective under
same confocal parameter settings (Figure 2A-2E). Cell
viability was indicated by an active enzymatic conversion
of the non-fluorescent calcein-AM to the greenfluorescent calcein in healthy cells (live cells), and con-
current uptake of the red fluorescent ethidium
homodimer-1 through damaged plasma membrane
(dead cells). The numbers of live (green) and dead (red)
cells under the above culture conditions were counted
using imageJ software (Figure 2F). Specifically, cells were
counted based on a randomized selection of four to five
areas of 1 mm2 under each culture condition. The mean
value of cell viability reflected by the percentage of live
cells was calculated and compared. Figure 2F shows the
statistic data demonstrating the effect of AgNPs on cell
viability under the control culture condition and in the
presence of different concentrations of AgNPs. Our data
show that AgNPs at all the concentrations examined sig-
nificantly compromised cell viability as compared to
control (P < 0.05). Specifically, the percent of live cells
under control conditions was 96.2 ± 1.6% (n = 4). It was
significantly reduced to 80.5 ± 3.1% (n = 4) by 1 μg/ml of
AgNPs, to 29.2 ± 1.8% by 5 μg/ml of AgNPs, to 33.2 ±
3.7% by 10 μg/ml of AgNPs, to 3.5 ± 0.7% by 50 μg/ml of
AgNPs (Figure 2F).
We next asked the question whether AgNPs affect
neuronal outgrowth that had been fully established in
the early stage of development (< 6 days). To answer
this, rat cortical neurons were first maintained in culture
for 4 days to allow extensive neuritic development. On
day 4, cells were exposed to culture medium only (as
control) or culture medium containing AgNPs at the
above concentrations. Cells were maintained in culture
for another 2 days. Phase contrast images (Figure 3A-
3D) were taken on day 6 followed by the Live/Dead cell
assay (Figure 2G). Specifically, control culture again
yielded healthy populations of cell bodies with extensive
interconnective processes (Figure 3A). Although cells ex-
posed to AgNPs at lower concentrations of 1 (Figure 3B)
and 5 (Figure 3C) μg/ml still exhibited extensive pro-
cesses and overlap, the majority of their cell bodies
started to show vacuoles, a typical sign for apoptosis (in-
dicated by asterisks). AgNPs, at the concentration of
10 μg/ml, not only severely compromised the morpho-
logical integrity of cell bodies, but also drastically caused
degeneration of neurites (Figure 3D). Accordingly, AgNPs
at 1 and 5 μg/ml reduced cell viability from control level
of 94.3 ± 1.0% to 86.2 ± 2.4% (n = 5, P > 0.05) and to 77.3 ±
3.6% (n = 5, P > 0.05), respectively (Figure 2G). However,
AgNPs significantly reduced cell viability from the control
level of 94.3 ± 1.0% to 72.7 ± 5.3% (n = 5, P < 0.05) by
AgNPs at 10 μg/ml and to 42.4 ± 8.2% (n = 5, P < 0.05) by
AgNPs at 50 μg/ml (n = 5, P < 0.001) (Figure 2G).
Finally, we sought to determine whether mature neu-
rons and their outgrowing patterns (> 10 days) could be
impacted after exposure to AgNPs. To examine this, rat
cortical cells were first cultured for 10 days. Neurons
were then treated with the carrier solution or carrier
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other 2 days. The effects of AgNPs were evaluated again
by phase contrast pictures (Figure 3E-3H) in combin-
ation with the Live/Dead cell assay (Figure 2H). At this
stage in the primary cell culture, neurons were fully de-
veloped and the glial cells actively formed solid layersFigure 2 (See legend on next page.)(as indicated by white open circles) in the culture dish
that surrounded and supported neurons and their
neurites. It was obvious that AgNPs, at 1 μg/ml, reduced
the intensity of neuronal branches and overlaps. Sur-
prisingly, AgNPs at 5 and 10 μg/ml, caused aggregation
of cell bodies into clusters, disruption of neurite
(See figure on previous page.)
Figure 2 The effect of AgNPs on cell viability of a developing and mature cortical culture. To assess the effect of AgNPs on cell viability at
the early stages of neuronal development, freshly isolated rat cortical cells were cultured either in the absence (control) or presence of AgNPs at
doses ranging from 1 μg/ml to 50 μg/ml. The cell viability/cytotoxicology assay was performed on day 3. The number of live and dead cells in
randomly chosen areas of 1 mm2 were counted using the imageJ program. The representative images are shown in A-E and the statistical data
of cell viability is presented in the bar graphs of F. Live cells are represented by the green fluorescence of calcein labeling of cell cytosol and
neurites, while dead cells are represented by the red fluorescent ethidium homodimer-1 indicating membrane damage. A-F reveals that when
cells were cultured in the presence of AgNPs, their viability and axonal outgrowth was decreased by AgNPs in a concentration-dependent
manner. To study how AgNPs affected cell viability at more developed stages, neurons and glia were first cultured in control medium for 4 days
(G) or 10 days (H) respectively, and both groups of cells were subsequently exposed to various concentrations of AgNPs for another 2 days. The
Live-dead cell assay was performed 2 days later. G-H show that AgNPs at concentrations greater than the 5 μg/ml significantly reduced cell
viability in both culture conditions. Statistical significance was determined using ANOVA one-way analysis of variance. Post hoc analysis was
conducted using Tukey’s test. * P < 0.05. ** P < 0.01. *** P < 0.001. Error bars indicate SEM for all figures. Scale bar, 25 μm.
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absence of glial layers in the culture dish (see white
open circles). In this case, disturbance of neurite con-
nections was not predominately observed as fragmenta-
tion of neurites, as seen in the early stage of cell culture
(Figure 4A-4D). Interestingly, the damage to neurons
and glia seemed to also result from mechanical insult
during cell aggregation. The Live/Dead cell assay
showed that AgNPs at both of 5 μg/ml (58.9 ± 3.2%, n =
5, P < 0.001) and 10 μg/ml (40.65 ± 1.8%, n = 5, P <
0.001), but not 1 μg/ml (96.9 ± 0.8%, n = 5, P > 0.05) sig-
nificantly reduced cell viability as compared to control
(97.6 ± 0.4%, n = 5) (Figure 2H).
Our data thus demonstrate that AgNPs not only in-
hibit neuritic initiation, extension and overlap, but also
cause degeneration of well-established neuronal struc-
tures leading to cell death.
AgNPs induce alterations in cytoskeletal components in
rat cortical neurons
The remarkable changes in cell morphology and viability
induced by AgNPs raised the question as to which
primary structures could likely be affected by AgNPs.
Because control conditions exhibit a high number of
neurons with a complex neuronal overlap and extensive
fluorescence labeling with both of β-tubulin and F-actin
antibodies. AgNP treatment reduced not only the number
of healthy cells, but also neuritic branches/overlap that
were labeled with F-actin and β-tubulin antibodies in a
concentration-dependent manner (Figure 4A-E, top two
panels). To further determine whether AgNPs affect cyto-
skeletal assembly/disassembly status in well-established
neurons and their neuritic processes, we first cultured neu-
rons for 4 days and allowed them to establish neurite pro-
cesses and overlaps. Cells were then maintained in culture
medium either lacking (control) or containing different
concentrations of AgNPs for another 3 days. Cells were
subsequently fixed and immunostained with either β-tubu-
lin/F-actin or β-tubulin/glial fibrillary acidic protein
(GFAP) antibodies in order to specifically label glial cells.
Figure 4F-4J (bottom two panels) show that cells culturedunder the control condition revealed extensive staining of
both neuronal β-tubulin (green) as well as the surrounding
glial structures. There was also high intensity of F-actin
(red) staining of these structures in control cultures
(Figure 4F). AgNP-treatment caused apparent deficits in
neuronal processes and cell body integrity (Figure 4G-4J).
To quantify the effect of AgNPs on the amount of cyto-
skeletal proteins, the fluorescent intensity of β-tubulin and
F-actin in randomly selected areas of 3844 μm2 under
each condition (as shown in Figure 4F-J) from four re-
peated experiments was measured using imageJ software.
Our statistic data show that AgNPs significantly reduced
the mean fluorescent intensity of both the β-tubulin (Fig-
ure 5A) and F-actin (Figure 5B) at the concentrations ex-
amined. Specifically, AgNPs at 1 μg/ml did not cause
noticeable changes in neuronal morphological integrity
(Figure 4G), it did however reduce the fluorescent inten-
sity of β-tubulin from the control level of 1611.6 ±
130.9 AU (n = 7) to 1022.1 ± 119.8 AU (n = 11) (P = 0.003),
and F-actin from the control level of 880.4 ± 100.8 AU
(n = 7) to 471.8 ± 96.7 AU (n = 11) (P = 0.0128). AgNPs at
concentrations above 5 μg/ml induced the apparent
degeneration of neuronal structures and dissolution of
F-actin and β-tubulin proteins (Figure 4H-J). Specifically,
the fluorescent intensity of β-tubulin was significantly re-
duced from the control level of 1611.6 ± 130.9 AU (n = 7)
to 723.0 ± 73.1 AU (n = 16, P < 0.001) by 5 μg/ml of
AgNPs, to 544.1 ± 58.5 AU (n = 14, P < 0.001) by 10 μg/ml
of AgNPs, and to 407.8 ± 67.4 AU (n = 8, P < 0.001) by
50 μg/ml of AgNPs (Figure 5A). The fluorescent inten-
sity of F-actin was significantly reduced from the con-
trol level of 880.4 ± 100.8 AU (n = 7) to 229.2 ± 30.7 AU
(n = 16, P < 0.001) by 5 μg/ml of AgNPs, to 117.2 ± 9.2 AU
(n = 14, P < 0.001) by 10 μg/ml of AgNPs, and to 93.4 ±
14.9 AU (n = 8, P < 0.001) by 50 μg/ml of AgNPs
(Figure 5B).
We next examined whether AgNPs affect glial cyto-
skeletal components. To do this, cells were first cultured
for 4 days and were then exposed to AgNPs at different
concentrations. On day 7, control and AgNP-treated
cultures were immunostained with antibodies of β-
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that specifically labels astrocytes. Our representative
fluorescent images in Figure 5C show that under the
control conditions, healthy neuronal soma (indicated by
a solid arrow) and neurites (indicated by an open arrow)Figure 3 (See legend on next page.)were surrounded by glial cells (indicated by asterisks).
The glial cells in the control were intensely labeled with
both the β-tubulin antibody (green) and the GFAP (red)
antibody. However cells that were treated with AgNPs at
10 μg/ml compromised neuronal soma morphology
(See figure on previous page.)
Figure 3 Exposure to AgNPs compromises neuronal viability and degenerates neuronal processes in well-established cells and
network. To assess whether AgNPs could cause neurotoxicity of cells that had established neurite processes during an early stage of
development, rat cortical cultures were first maintained in control culture medium for 4 days and allowed to develop processes and overlaps.
Cultures were subsequently exposed to culture medium containing AgNPs at 0 (control-A), 1 (B), 5 (C), and 10 (D) μg/ml for 2 days. Phase
contrast pictures were taken on day 6. To assess the consequence of AgNP exposure at a later stage of development, rat cortical cultures were
first maintained in control culture medium for 10 days and allowed to develop a mature, well-endowed network; cells were subsequently
exposed to culture medium containing AgNPs at 0 (control-E), 1 (F), 5 (G), and 10 (H) μg/ml for another 2 days. Phase contrast pictures were
taken on day 12. Under both culture conditions, AgNPs at high concentrations (> 5 μg/ml) compromised cellular membrane integrity and
induced neurite degeneration. It is however interesting to note that AgNPs induced fragmentation of neurites at the early stage of cell culture
(C-D), while triggered an aggregation of cells bodies and thinning of neurite processes in the later stage of cell culture (G-H). In addition, glial cell
layers (indicated by white circles) were present under the control (E) and 1 μg/ml (F) of AgNP- treated cultures, but were absent in cultures that
were exposed to AgNPs at the concentrations of 5 (G) and 10 (H) μg/ml. Scale bar, 25 μm.
Figure 4 AgNPs induce reduction or alteration of cytoskeletal components, β-tubulin and F-actin, in rat cortical primary cultures.
We first assessed the effect of AgNPs on neuronal cytoskeleton initiation and outgrowth in cells cultured either in the absence (control) or
presence of different concentrations of AgNPs for 3 days (A-E, via a 20× objective). We also examined whether AgNPs could affect well-
established cytoskeleton network in cells that have been cultured for 4 days and were then exposed to various concentrations of AgNPs (F-J,
via a 63× oil objective). In both sets of experiments, control neurons displayed high fluorescence intensity of β-tubulin (green) and F-actin (red),
which labeled healthy cell bodies and dense neuritic overlaps. AgNP-treatment increased cell death in combination with a reduction in β-tubulin
branching and overlapping (also see inserted phase contrast images). AgNPs also reduced the degree and intensity of red fluorescent labeling of
F-actin in AgNP-treated cultures.
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Figure 5 Statistical data showing the effect of AgNPs on the
mean fluorescent intensity of cytoskeletal proteins and
representative images showing the impact of AgNPs on glial β-
tubulin and GFAP. To quantify the effect of AgNPs on the level of β-
tubulin and F-actin, the fluorescent intensity of randomly selected 7-16
areas of 3844 μm2 under control and AgNP-treated conditions (as
shown in Figure 4F-4J) were measured using imageJ software. The
quantified data show that AgNPs significantly decreased the fluorescent
intensity of both β-tubulin (A) and F-actin (B). To further investigate
whether AgNPs affected glial cytoskeleton, cells were co-stained with β-
tubulin (green) and GFAP (red), a specific marker for glial astrocytes. C
shows the representative images of cells in the control and AgNPs at
10 μg/ml. Neurons under the control conditions exhibited healthy
neuronal cell bodies (indicated by a solid arrow) and neurites (indicated
by an open arrow), while neurons exposed to 10 μg/ml of AgNPs had
degenerated cell bodies (indicated by a solid arrow) and neurites
(indicated by an open arrow). Note that both of the β-tubulin and GFAP
in glial cells (indicated by asterisks) were compromised by AgNPs. * P <
0.05. ** P < 0.01. *** P < 0.001. Error bars indicate SEM. Scale bar, 20 μm.
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cated by an open arrow). Notably, the fluorescent intensity
of red GFAP and green β-tubulin in glial cells (indicated
by asterisks) was remarkably affected by AgNPs (Fig-
ure 5C). In summary, our data demonstrate that the major
components of neuronal and glial cytoskeletal proteins, β-
tubulin and F-actin, were affected by AgNPs.
AgNPs induce alterations in pre- and postsynaptic
proteins in rat cortical neurons
Cytoskeletal components not only serve as fundamental
structures for cell integrity and survival, but also play a
pivotal role in supporting, organizing and trafficking of
synaptic elements, which are crucial for neuronal com-
munication and synaptic plasticity [19-21]. Thus, the
disturbance of cellular cytoskeletal components may
thus have an effect on synaptic structures and functions.
To this end, we investigated whether AgNPs could affect
synaptic proteins such as synaptophysin, a presynaptic
vesicle protein, and PSD-95, a postsynaptic density pro-
tein, that play important roles in synaptic transmission,
synapse maturation and synaptic plasticity [22,23]. To
do this, we cultured cortical neurons for 10 days and
allowed for the establishment of a network and matur-
ation of synaptic components. Cells were then exposed
to culture medium either in the absence (control) or
presence of AgNPs at different concentrations for 2 days.
The effect of AgNPs on the expression level and cluster-
ing of synaptic proteins, synaptophysin and PSD-95 were
examined on day 12 using immunofluorescence staining
and confocal microscopy. Figure 5 shows that control
neurons displayed extensive dendritic arborization and
mature synaptic contacts, evident by distinct punctate
labeling with a presynaptic marker of synaptophysin and
a postsynaptic marker of PSD-95 (also see inserts). Cells
exposed to AgNPs even at 1 μg/ml revealed a remark-
able decline in the density of fluorescence buttons,
although they maintained a integrative somatic and
neuritic morphology, indicating the degradation of
synaptic proteins of both synaptophysin and PSD-95
(Figure 5B, also see insert). AgNPs, at a high concentration
of 10 μg/ml, induced not only severe damage to the neur-
onal network integrity but also robust degradation of synap-
tic proteins (Figure 5C, also see insert). Because of the
severe deficit in neuronal structural integrity at high con-
centrations of AgNPs, it was difficult to not only distinguish
dendrites from axons, but also to quantify the density of
buttons in the same length of dendrites. We were however
able to measure and compare the mean fluorescent inten-
sity of neuronal synaptophysin and PSD-95 in areas of
1340 μm2 under control and AgNP-treated conditions. Our
quantified data from four repeated experiments demon-
strated that the fluorescent intensity of both presynaptic
synaptophysin and postsynaptic PSD-95 was signifi-
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(Figure 6D and 6E). Specifically, the level of fluorescent
intensity of synaptophysin under control conditions was
333.3 ± 36.7 AU (n = 13) and it was reduced to 208.2 ±
21.5 AU (n = 12, P = 0.04) by 1 μg/ml of AgNPs, to
201.0 ± 28.0 AU (n = 12, P = 0.04) by 5 μg/ml of AgNPs,
and to 139.3 ± 8.8 AU (n = 12, P < 0.001) by 10 μg/ml of
AgNPs. Similarly, the level of fluorescent intensity of
PSD-95 under control conditions was 550.0 ± 50.3 AU
(n = 13) and it was reduced to 396.8 ± 39.2 AU (n = 12,
P = 0.03) by 1 μg/ml of AgNPs, to 356.4 ± 35.1 AU (n = 12,
P = 0.005) by 5 μg/ml of AgNPs, and to 342.2 ± 44.28 AU
(n = 12, P = 0.002) by 10 μg/ml of AgNPs.
Assessment of mitochondrial integrity after AgNP
treatment
There is increasing evidence linking mitochondria to cell
death, abnormal cytoskeletal and synaptic proteins in a
variety of cell preparations [24-26]. To assess whether
AgNPs affect the integrity and function of mitochondria,
we simultaneously stained cells with MitoTracker Red, a
specific marker for mitochondria, and calcein AM, an
indicator of cell viability. To do this, cells were cultured
in the absence of AgNPs for 4 days, which allowed for
development of healthy neurites and networks. Cells
were then exposed to AgNPs for another 2 days. On day
6, cells were loaded with MitoTracker Red and calcein
AM for 15 mins at 37°C. Fluorescent images were ac-
quired using confocal microscopy (Nikon, USA) under a
60× water objective. In viable cells, calcein AM enters
cell cytosol as well as in the mitochondria and emits
green fluorescence in both structures. The MitoTracker
Red selectively marks the presence of mitochondria and
its uptake relies upon potential gradient across mito-
chondrial membrane. The overlapping yellow color indi-
cates simultaneous and active intake of both dyes and
the amount of fluorescent intensity indicate the func-
tional degree of mitochondria in the uptake of these two
dyes. As shown in Figure 7A, control neurons (indicated
by open arrows) and glial cells (indicated by solid ar-
rows) reveal healthy cell bodies and neuronal processes
displayed by the intense green fluorescence of calcein
and MitoTracker Red in these structures. The intensive
and high incidence of co-labeling (yellow) of mitochon-
dria designates the functional integrity of mitochondria
in control cells (Figure 7A). Our data analysis from four
experiments revealed that under control conditions, the
green fluorescent intensity of calcein in areas of
3800 μm2 was 534.6 ± 79.1 AU (n = 8) and the red fluor-
escent intensity of MitoTracker Red was 452.8 ±
100.8 AU (n = 8) (Figure 7D & 7E). The fluorescent in-
tensity of both calcein and MitoTraker Red dyes was
however significantly reduced by 1 μg/ml of AgNPs to
293.7 ± 33 AU (n = 9, P = 0.003) and 223.9 ± 44.4 AU(n = 9, P = 0.02), respectively. Specifically, cells exposed
to 1 μg/ml of AgNPs for 2 days exhibited compromised
cell morphological integrity in combination with reduced
intensity of green and red fluorescence (Figure 7B).
The absence of green fluorescence in MitoTracker
Red-labeled mitochondria (indicated by solid arrows) in-
dicated the lack of active esterase in mitochondria or
a leak of green calcein from injured mitochondria
(Figure 7B). The minimum co-localization of green and
red in higher concentrations of AgNPs (e.g. 5 μg/ml,
Figure 7C)-treated cells further indicated the detrimental
effect of AgNPs on mitochondrial functionality. As
shown in Figure 7D and 7E, the fluorescent intensity of
calcein was significantly reduced to 220.1 ± 28.8 AU
(n = 11, P < 0.001) by 5 μg/ml of AgNPs and to 200.4 ±
21.9 AU (n = 11) by 10 μg/ml of AgNPs. The fluorescent
intensity of MitoTracker Red was reduced to 175.4 ±
24.5 AU (n = 11, P = 0.003) by 5 μg/ml of AgNPs and to
151.1 ± 25 AU (n = 11) by 10 μg/ml of AgNPs.
Discussion
The present study provides the first morphological and
cellular evidence that exposure to AgNPs results in a
reduction in synaptic proteins, cytoskeletal integrity,
mitochondria functionality and cell viability in a
dose-dependent manner. Specifically, AgNPs not only
inhibited neurite extension and overlap during the early
stage of neuronal development, but also caused degener-
ation of neuritic processes or aberrant aggregations of
cell bodies in well-established neurons and their net-
works. AgNPs-induced neurotoxicity involved altering
cytoskeletal proteins (e.g. β-tubulin and F-actin), dissol-
ution of synaptic proteins (e.g. synaptophysin and PSD-
95), and compromising of mitochondria function. Our
data show that the AgNP – induced reduction of cellular
viability occurs in all types of cells in the primary cul-
ture. Recent awareness has raised concerns regarding
the impact of environmental factors (e.g. heavy metals,
pesticide etc) on human and animal health involving a
wide range of diseases including cancer, liver, lung, and
kidney diseases as well as brain disorders. Our study
together with several published accounts thus cautions
against the chronic and extensive use of AgNPs in
products that may come in direct contacts with all living
organisms [7,13-15].
With the noteworthy maturation of nanotechnology dur-
ing the last decade, nanoparticle products will continue to
be used increasingly in our everyday commercial products,
industrial processes and medical applications. Such exten-
sive and unregulated exposure to ultrafine-size substances
released either into the atmosphere and/or water system,
food and therapeutic products holds potential hazardous
risks not only to humans but also to all organisms [27-30].
Recent studies have revealed that AgNPs, one of the most
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mental deficits not only in aquatic animals but also aquatic
plants [31,32]. Owing to their antibacterial properties,
AgNPs have been predominately used for the developmentFigure 6 (See legend on next page.)of medicines, drug delivery systems and medical device
coatings [4,7]. AgNPs can be translocated to the blood
stream and distributed throughout vital organs such as the
liver, kidney, lung and brain [4,5,11]. AgNPs can cross the
Figure 7 Cell viability and mitochondria staining of rat cortical
cultures under control and AgNP-treated conditions. Cells were
first cultured for 4 days and subsequently exposed to AgNPs at 1, 5,
and 10 μg/ml for another 2 days. On day 6, MitoTracker Red, a
selective mitochondria marker and calcein AM, an indicator of cell
viability, were loaded in control and AgNP-treated cultures.
Representative images show that cells maintained in control culture
medium (A) displayed intense green fluorescence staining of healthy
structures of all cell types including neurons (indicated by open
arrows) and glial cells (indicated by solid arrows). These cells also
contain intense and well-organized labeling of mitochondrial
structures by the red fluorescent MitoTracker Red dye. Co-localized
spots (yellow) likely represent the location of intact and functional
mitochondria. However, AgNP-treated cells (B and C) drastically lost
the green fluorescence intensity and a degree of yellow staining
indicating that AgNPs induced decrease of cell viability is
accompanied by mitochondrial dysfunction. Statistical analysis
shows that the fluorescent intensity of both calcein (D) and
MitoTracker Red (E) was reduced significantly by AgNPs. Statistical
significance was determined using ANOVA one-way analysis of
variance. Post hoc analysis was conducted using Tukey’s test. * P <
0.05. ** P < 0.01. *** P < 0.001. Error bars indicate SEM.
(See figure on previous page.)
Figure 6 Immunostaining study of the presynaptic vesicle membrane protein synaptophysin (green), and the postsynaptic marker
PSD-95 (red) in control and AgNP-treated neurons. To examine how AgNPs affect synaptic structural and functional components, cells were
first cultured for 10 days and allowed to develop synaptic structures. Cells were then exposed to AgNPs at 1, 5, and 10 μg/ml for another 2 days.
Neurons were then incubated with antibodies against synaptophysin and PSD-95. Neurons kept under control culture conditions (A, also see
inserts) showed extensive neuritic processes in which dense puncta labeling of the synaptic vesicle protein synaptophysin (green) was observed.
In addition, both cell bodies and dendritic neurites exhibit high intensity of red fluorescent labeling of PSD-95. Co-localized spots (yellow)
represent the location of potential synapses. However, AgNP treatment even at low concentration of 1 μg/ml drastically reduced both the green
fluorescent synaptophysin and red fluorescent PSD-95 (B). The reduction in fluorescent intensity of synaptic proteins by AgNPs at the 10 μg/ml
was accompanied by injured cell morphology and compromised network integrity (C). The data shows that the mean fluorescent intensity of
both the synaptophysin (D) and PSD-95 (E) was significant decreased by AgNPs at the concentrations examined. Scale bars, 20 μm (A,B,C) and
5 μm (inserts).
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ability indicating the potential risk for toxicity to the brain
[5,10,12]. While the literature is silent on the precise con-
centrations of AgNPs found in the brain as it crosses the
BBB, several studies have reported that the rate of nanopar-
ticle translocation into the brain can be significantly in-
creased under certain pathological conditions, such as
infection, meningitis, systemic inflammation etc [8,13]. Our
choice of AgNP concentration and size was based on previ-
ously established works. AgNPs (20 nm) were used due to
their known high cytotoxic properties with respect to per-
meating and damaging cerebral microvascular structures,
as compared with larger particles (40 nm and 80 nm) [12].
Similarly, smaller nanoparticles (20 nm) have also been
shown to induce higher levels of cellular oxidative damage
[16]. Previous experiments conducted with 20-40 nm
AgNPs used concentrations ranging from 1 to 100 μg/ml
to examine the potential hazardous effects of AgNPs with
primary neuronal cells [16-18,33]. In these studies, AgNPs
have been found to inhibit neuronal sodium and potassium
currents at 10 μg/ml, disturb neuronal calcium homeostasis
at 5 μg/ml, and reduce dopamine concentration at 50 μg/
ml. Based on these studies, we pursued to identify the ef-
fects of chronic exposure to AgNPs (20 nm) at the low to
medium doses of 1, 5, 10 and 50 μg/ml on the primary rat
cortical cell viability, cytoskeletal frameworks, key synaptic
proteins, and mitochondrial function.
Because all brain functions rely critically upon the nor-
mal development of neuronal structures and network
circuitry, any perturbation of these processes will render
the nervous system dysfunctional. In the course of neur-
onal development, cell viability and neurite outgrowth
are two fundamental and essential factors enabling
neurons to reach their potentials targets and establish
functional communications. These steps rely upon the
integrity of cytoskeletal structures. Specifically, cytoskel-
etal components play imperative roles in neuronal
architecture formation and maintenance such as neurite
outgrowth, axon guidance, information transmission,
and functional synaptic circuitry establishment [34-36].
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processes by β-tubulin and F-actin antibodies in cells
cultured in the presence of AgNPs indicate that AgNPs
may inhibit neurite initiation and sprouting by disturbing
the assembly/disassembly of these cytoskeletal proteins.
The intact cytoskeleton also plays an indispensible role in
the localization and trafficking of synaptic machinery (neu-
rotransmitters/receptor proteins) and intracellular organ-
elles including the mitochondria. The degeneration of
microtubule and neurofilament components by AgNPs in a
well-established neuronal network may directly or indir-
ectly contribute to AgNP-induced loss of synaptic proteins
(eg. PSD-95 and synaptophysin, Figure 6) and injury of
mitochondria (Figure 7). One would need to be aware that
AgNPs might first cause impairment of synaptic proteins
and/or mitochondria which may in turn, deprive the funda-
mental cytoskeletal structures of their vitality source and
hence the ensuring collapse. Future studies using time-
lapse imaging in combination with fluorescent tagging
techniques will be required to investigate these possibilities
further. Nevertheless, our data does indicate that by
curtailing the growth patterns of neurons, AgNP may not
only prevent normal brain development but also preclude
neuronal plasticity, learning and memory that relies upon
new growth of process and synapses.
We found that exposure to AgNPs exerted detrimental
effects on all types of cells including glial cells present in
the primary, rat cortical cultures. It is well appreciated
that glial cells not only play crucial supportive roles in
the development and maintenance of neuronal struc-
tures, but that they also actively communicate with neu-
rons to enable synapse formation, synaptic transmission,
plasticity and synaptic homeostasis [37,38]. The pro-
nounced loss of glial cells or their ability to form layers
in AgNP-treated cultures (Figure 3) indicates that the
glial cell morphology can be severely compromised by
AgNPs. This finding is further supported by our immu-
nostaining of glial cell cytoskeletal β-tubulin and GFAP
(Figure 5C) in which glial microtubules and intermediate
filament proteins were compromised in AgNP-treated
culture, while intense green labeling of glial β-tubulin
and GFAP was evident in control cultures. This data
suggests that components of the glial cytoskeleton are
the major target for AgNP-induced toxicity in glial cells.
Our findings are consistent with a previous study dem-
onstrating that the glial cell astrocytes were more sensi-
tive to AgNP insult than neurons [16]. Glial cells also
play guiding and adhesion roles during neuronal net-
work formation [39-41], hence any absence of preferred
neuronal adhesion to glia may contribute to AgNP-
induced aggregation of cell bodies and neurofibrillary
processes that were observed in our study (Figure 3G
and 3H). In addition, a lack of proper innervations and
communications between neurons and neuroglia mayalso markedly deprive them of their glial trophic support.
Moreover, in the absence of glial neuro-protection, the
neurotoxic effects of AgNPs may have also been exacer-
bated. These in turn may also impact synaptic transmis-
sion, deteriorate synaptic components, and eventually lead
to cell death. Synaptic damage has been implicated in a
variety of brain disorders, including traumatic nerve in-
jury, stroke, and many neurodegenerative disorders, such
as Alzheimer’s, Parkinson’s and Huntington’s diseases
[42-44]. Alterations to synaptic structures rank among the
earliest notable features in the commencement of the cog-
nitive decline characterized and represented in the co-
morbidity of Alzheimer’s diseases [45]. In fact, studies
have shown that normal animals treated with AgNPs
exhibited reduced cognitive/motor functions and altered
cellular structures in the brain [13]. This study together
with our data showing the AgNP toxicity to nervous tis-
sues at the cellular, molecular and system levels during
both developing and mature stages advise against the po-
tential chronic exposure to AgNPs not only in young
people whose brains undergo rapid development, but also
in adults whose cognitive functions require continued
growing of new neuronal networks.
Conclusions
Taken together, this study demonstrates the potentially
devastating effects of AgNPs on cell survival, synaptic
protein localization, cytoskeletal proteins, and mitochon-
drial integrity. Based on the fact that AgNPs have
emerged as an important class of nano materials for a
wide range of industrial and medical applications, our
study highlights not only an urgent need to assess their
potential health risks at the whole organism level but
also to develop strict policies for their usage.
Methods
Rat cortical cultures
All animal procedures were approved by the University
of Calgary Animal Care Committee. Conditions met
with the standards established by the Canadian Council
on Animal Care. The primary culture of rat cortical cells
was made using Sprague–Dawley rat pups at postnatal
day zero. Dissociated cortical neurons were plated onto
cover slips coated with poly-D-lysine (30 μg/ml,
Sigma P6407) and Laminin (2 μg/ml, Sigma L2020).
Cortical neurons were cultured in neurobasal medium
(Invitrogen, no. 21103-049) supplemented with 2% B27
(Invitrogen, no. 17504-044), L-Glutamine (200 mM)
(Invitrogen, no. 25030-081), 4% FBS (Invitrogen, no.
12483-020), and penicillin-streptomycin (Invitrogen, no.
15140-122). Approximately 80% of the culture media
was replaced every 3-4 days. Cultures were maintained
at 37°C in an incubator circulated with air and 5%
carbon dioxide.
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tiation, neurite outgrowth and overlap, freshly dissoci-
ated cortical neurons were cultured either in the
absence (control) or presence of different concentrations
of AgNPs (1, 5, 10 and 50 μg/ml) for 3 days. Neurite
outgrowth and cell viability were evaluated on day 3. To
examine the effect of AgNPs on newly established neur-
onal processes and overlaps, cells were first cultured for
4 days to allow for the establishment of neurite out-
growth and network. Neurons were then exposed to
AgNPs at different concentrations for 2 days, and the ef-
fects of AgNPs were examined. To study the effect of
AgNPs on well-established mature network, 10 day-old
cells cultured on cover slips were exposed to different
concentrations of AgNPs for two days and the effects
were evaluated on day 12.
Live/dead cell viability assay for cortical cells
To determine and quantify the impact of AgNPs on cell
viability, cortical cultures that were maintained under con-
trol or drug-treated conditions were subsequently loaded
with the LIVE⁄DEAD® Viability⁄Cytotoxicity Kit (Molecular
probes, L-3224) for 15 mins at room temperature (21-22°C).
This two-color assay was developed based on the fact
that intracellular esterase activity and an intact plasma
membrane are unique characteristics of live cells. The LIVE⁄
DEAD® Viability⁄Cytotoxicity Kit discriminates live from
dead cells by simultaneously staining with green-fluorescent
calcein-AM to indicate intracellular esterase activity and
red-fluorescent ethidium homodimer-1 to indicate loss of
plasma membrane integrity. Preparations were visualized
using confocal microscopy (LSM 510 Meta, Zeiss, Germany)
under a 20× objective at 488 nm excitation (green) and
548 nm (red) wavelength and images were collected using
a band pass filter (560-615 nm). The number of cells labeled
with both colors was subsequently counted using imageJ
software.
Immunochemistry and confocal microscopy
To stain the cytoskeletal proteins of β-tubulin and
F-actin, cultured cells were fixed for 1 h with pre-
warmed 4% paraformaldehyde and subsequently washed
four times with 1× PBS and permeabilized for 1 h with
incubation media (IM) (0.5% Triton in 1× PBS with 10%
goat serum). Preparations were then incubated overnight
at 4°C with a monoclonal anti-β-tubulin antibody pro-
duced in mouse (1:500) (Sigma, T0198). The next day,
cells were rinsed twice with 1× PBS and incubated with
Alexa Fluor® 488 goat anti-mouse IgG secondary anti-
body (1:100) (Invitrogen, A-11001) for 1 h at room
temperature (21-22°C) under dark conditions. Cultures
were subsequently rinsed two times with 1× PBS and
incubated for 30 minutes with rhodamine phalloidin
(1:20) (Invitrogen, R415) at room temperature. Followingtwo washes with 1 × PBS and one quick rinse with
double distilled H2O, cover slips were mounted using
MOWIOL mounting media with 4′6-diamidino-2-
phenylindole dihydrochloride (Sigma-Aldrich). Samples
were viewed using confocal microscopy (LSM 510 Meta,
Zeiss, Germany) under a 20× or 63× oil objective at
488 nm (green, β-tubulin) and 548 nm (red, F-actin) ex-
citation wavelengths. Images were collected using a band
pass filter (560-615 nm). To stain glial cytoskeletal pro-
teins, the mouse monoclonal anti-β-tubulin antibody
(1:200) (Sigma, T0198) and rabbit monoclonal anti-
GFAP antibody (1:200) (Biomedical Technologies Inc.,
BT-575) were stained following procedures as described
above. The secondary antibodies were Alexa Fluor® 488
goat anti-mouse IgG antibody (1:100) (Invitrogen, A-
11001) and Alexa Fluor® 546 goat anti-rabbit IgG
antibody (1:100) (Invitrogen, A-11010). Image acquisi-
tion parameters (e.g. laser intensity, gain settings,
pinhole sizes, exposure time etc) for control and drug-
treated neurons were kept the same. Negative control
experiments were performed at the same time to test the
specificity of ß-tubulin, F-actin, and GFAP antibodies.
No immunofluoresecence was detected when primary
antibodies were excluded from the staining procedures
(see Additional file 1A and 1B). To verify whether neu-
rons exhibited autofluorescence, unstained cells were ex-
cited with all lasers (633, 488, 546 nm) of the confocal
microscope and no autofluorescence was observed (data
not shown).
To stain the synaptophysin and PSD-95, cultured cells
were fixed with pre-warmed 4% paraformaldehyde and
15% picric acid at room temperature (21-22°C) for 20
mins. Cells were subsequently washed four times with
1× PBS and permeabilized for 1 h with blocking incuba-
tion media (0.1% Triton in 1× PBS with 5% goat/donkey
serum and 2% BSA). Preparations were then incubated
overnight at 4°C with the monoclonal anti-PSD-95 anti-
body produced in mouse (1:2000) (NeuroMab, 75-028)
and an anti-synaptophysin monoclonal antibody pro-
duced in rabbit (1:500) (Abcam, Ab52636). The next day
cells were rinsed twice with 1× PBS. Cells were then in-
cubated with Alexa Fluor® 488 goat anti-rabbit IgG
secondary antibody (1:100) (Invitrogen, A-11001) and
Alexa Fluor® 546 goat anti-mouse IgG secondary anti-
body (1:100) (Invitrogen, A11030) for 1 h at room
temperature (21-22°C) under dark conditions. Following
two washes with 1× PBS and one quick rinse with
double distilled H2O, cover slips were mounted using
MOWIOL mounting media with 4′6-diamidino-2-
phenylindole dihydrochloride (Sigma-Aldrich). Samples
were viewed using confocal microscopy (LSM 510 Meta,
Zeiss, Germany) under a 63× oil objective at 488 nm excita-
tion (green, synaptophysin) and 548 nm (red, PSD95)
wavelength. Images were collected using a band pass filter
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PSD-95 staining, image acquisition parameters (laser
intensity, gain settings, pinhole sizes, exposure times etc)
for control and drug-treated neurons were kept the same.
As a specificity control for the immunostaining, no im-
munofluorescence was observed when primary antibodies
of synaptophysin and PSD-95 were excluded from the
above staining procedures (see Additional file 1C and 1D).
To assess the impact of AgNPs on the integrity and
function of mitochondria, cortical cultures were first
maintained in control medium for 4 days and cells were
then exposed to AgNPs for another 2 days. On day 6,
control or drug-containing medium was subsequently
washed off twice with warm Hanks’ Balanced Salt Solu-
tion (HBSS) containing sodium bicarbonate, calcium,
and magnesium that also included HEPES (10 mM), L-
glutamine (2 mM) and succinate (100 μM) to support
healthy mitochondrial function in live cells. Cells were
then incubated in a dye-loading solution containing
calcein AM (1 μM) and MitoTracker Red CMXRos
(200 nM) for 15 mins at 37°C. Fluorescence images of
mitochondrial integrity (red) and cell viability (green)
were collected using a Nikon Eclipse C1si Spectral
Confocal microscope with motorized stage (Nikon
Instruments Inc., Melville, NY, United States) at the
excitation wavelength of 561 nm (red, with a 590/50
emission filter) and 488 nm (green, with a 515/30 emis-
sion filter) through a 60× water objective. Again, image
acquisition parameters for control and drug-treated
neurons were kept the same.
Chemicals
Silver nanoparticles (AgNPs) were purchased from
nanoComposix (Sandiego, CA, USA). All chemicals were
purchased from Sigma-Aldrich (Oakville, Ontario, Canada).
Statistical analysis
Data was analyzed statistically using one-way analysis of
variance (ANOVA) as appropriate. Post hoc analysis was
conducted using Tukey’s test. Values were considered
statistically significant at the level of P < 0.05. The data is
presented as mean ± S. E.M. Each experiment was repli-
cated a minimum of four times; the actual number of
replicates for each experiment is listed in the corre-
sponding figure legend or in the text.
Additional file
Additional file 1: Specificity of antibody staining. To test for the
specificity of antibodies (β-tubulin, GFAP, synaptophysin and PSD-95) staining,
control experiments in which the primary antibodies were excluded were
performed at the same time following procedures as described in the
method section. When primary antibodies were excluded from the staining
procedure, no immunofluorescence was observed (B- without β-tubulin/GFAP;
D-without synaptophysin/PSD-95). In contrast, intense immunofluorescencewas detected when primary antibodies were included (A-with β-tubulin/GFAP;
C- with synaptophysin/PSD-95). Note that because all the antibodies used
were monoclonal (as described in the Methods), we therefore did not
perform antigen pre-absorption test for polycolonal antibodies.Competing interests
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